BREAKING ADVANCES

4007  Highlights from Recent Cancer Literature

OBITUARY

4009  Donald Lee Morton: In Memoriam (1934–2014)
Dave S.B. Hoon

REVIEWS

4011  Role of the Neural Niche in Brain Metastatic Cancer
John Termini, Josh Neman, and Rahul Jandial

4016  Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?
Christos Hatzis, Philippe L. Bedard, Nicolai J. Birkbak, Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern, Leming Shi, Robert Clarke, John Quackenbush, and Benjamin Haibe-Kains

PERSPECTIVE

4024  The Increasing Urgency for Standards in Basic Biologic Research
Leonard P. Freedman and James Inglese

MICROENVIRONMENT AND IMMUNOLOGY

4030  Microbiota Modulate Tumoral Immune Surveillance in Lung through a γδ T17 Immune Cell-Dependent Mechanism
Min Cheng, Liting Qian, Guodong Shen, Geng Bian, Tingjian Xu, Weiping Xu, Gan Shen, and Shilian Hu

MOLECULAR AND CELLULAR PATHOBIOLOGY

4053  GPER Mediates Activation of HIF1α/VEGF Signaling by Estrogens
Ernestina Marianna De Francesco, Michele Pellegrino, Maria Francesca Santolla, Rosamaria Lappano, Emilia Ricchio, Sergio Abonante, and Marcello Maggiolini

PREVENTION AND EPIDEMIOLOGY

4065  Recent Prediagnostic Aspirin Use, Lymph Node Involvement, and 5-Year Mortality in Women with Stage I–III Breast Cancer: A Nationwide Population-Based Cohort Study
Thomas I. Barron, Evelyn M. Flahavan, Linda Sharp, Kathleen Bennett, and Kala Visvanathan

4078  Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age
Elisabeth F. Beaber, Diana S.M. Buist, William E. Barlow, Kathleen E. Malone, Susan D. Reed, and Christopher I. Li

Precis: Breast cancer risk appears to be increased by recent use of contemporary oral contraceptives, with some variation in this risk possibly associated with different formulations.
4090  Telomere Length in White Blood Cell DNA and Lung Cancer: A Pooled Analysis of Three Prospective Cohorts  
**Précis:** Positive associations between telomere length in white blood cells and risk of lung cancer open an interesting new perspective on how immune cell alterations may affect susceptibility to this type of cancer.

**THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY**

4099  Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer  
Robert T. Dauchy, Shulin Xiang, Lulu Mao, Samantha Brimer, Melissa A. Wren, Lin Yuan, Muralidharan Anbalagan, Adam Hauch, Tripp Frasch, Brian G. Rowan, David E. Blask, and Steven M. Hill  
**Précis:** Striking demonstrations in a preclinical model of estrogen-dependent breast cancer show how disrupting normal circadian patterns of melatonin production by exposure to light at night can cause resistance to tamoxifen therapy.

4111  Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolytic Kinetics and Tumor Viability  
**Précis:** Methods to image the replication cycles of oncolytic viruses noninvasively in vivo will assist the clinical development of this class of experimental therapeutics by helping identify virus expansion during dose escalation studies.

4122  Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor  
Curtis H. Kugel III, Edward J. Hartsough, Michael A. Davies, Yulius Y. Setiady, and Andrew E. Aplin  
**Précis:** This study provides a preclinical rationale to combine a RAF inhibitor with an ERBB3/HER3-neutralizing antibody to improve durable therapeutic responses in melanomas harboring BRAF V600E mutations.

4133  Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response  
Jiusheng Deng, Shala Yuan, Andrea Pennati, Jordan Murphy, Jian Hui Wu, David Lawson, and Jacques Galipeau  
**Précis:** This preclinical study introduces a chimeric cytokine composed of GM-CSF and IL4 that is a powerful inducer of melanoma-eradicating B cells, suggesting its candidacy as a novel immunotherapeutic tool and revealing a previously unrecognized potential for B cells in melanoma immunotherapy.

**TUMOR AND STEM CELL BIOLOGY**

4145  miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1  
Roberto Dinami, Cristiano Ercolani, Eleonora Petti, Silvano Piazza, Yari Ciani, Rosanna Sestito, Andrea Sacconi, Francesca Biagioni, Carlos le Sage, Reuven Agami, Roberta Benetti, Marcella Mottola, Claudio Schneider, Giovanni Blandino, and Stefan Schoeftner  
**Précis:** These findings highlight an miRNA-mediated mechanism for controlling telomere function, suggesting the existence of a class of "telo-miRNAs" with an impact on cancer and aging.

4157  miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1  
Roberto Dinami, Cristiano Ercolani, Eleonora Petti, Silvano Piazza, Yari Ciani, Rosanna Sestito, Andrea Sacconi, Francesca Biagioni, Carlos le Sage, Reuven Agami, Roberta Benetti, Marcella Mottola, Claudio Schneider, Giovanni Blandino, and Stefan Schoeftner  
**Précis:** These findings highlight an miRNA-mediated mechanism for controlling telomere function, suggesting the existence of a class of "telo-miRNAs" with an impact on cancer and aging.

4167  An Inducible Hepatocellular Carcinoma Model for Preclinical Evaluation of Antiangiogenic Therapy in Adult Mice  
Anja Runge, Junhao Hu, Matthias Wiedand, Jan-Philipp Bergeest, Carolin Mogler, André Neumann, Cyrill Geréaud, Bernd Arnold, Karl Rohr, Dorde Komljenovic, Peter Schirmacher, Sergij Goerdt, and Hellmut G. Augustin  
**Précis:** This study validates a versatile inducible model of hepatocellular carcinoma (HCC) in adult mice for the study of multinodular HCC tumorigenesis and response to therapy during tumor progression.

4170  Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties  
**Précis:** The findings of this study identify YAP1-driven SOX9 expression as a critical event in acquisition of CSC properties in nontransformed cells and esophageal cancer cells and suggest that pharmacologic inhibition of YAP1 may be an effective means of targeting the CSC population.
miRNA-128 Suppresses Prostate Cancer by Inhibiting BMI-1 to Inhibit Tumor-Initiating Cells
Min Jin, Tao Zhang, Can Liu, Mark A. Badeaux, Bigang Liu, Ruifang Liu, Collene Jeter, Xin Chen, Alexander V. Vlassov, and Dean G. Tang

Precis: These results define a tumor suppressor function for an miRNA that limits prostate cancer by blocking the properties of cancer stem-like cells in that setting, with potential implications to improve the treatment of recurrent disease driven by these cells.

ABCB5 Maintains Melanoma-Initiating Cells through a Proinflammatory Cytokine Signaling Circuit
Brian J. Wilson, Karim R. Saab, Jie Ma, Tobias Schatton, Pablo Pütz, Qian Zhan, George F. Murphy, Martin Gasser, Ana Maria Waaga-Gasser, Natasha Y. Frank, and Markus H. Frank

Precis: These findings define a novel function for a drug efflux transporter molecule in cancer stem-like cell maintenance, possibly explaining its broad overexpression in many types of human cancer.

Correction: Potentiation of the Novel Topoisomerase I Inhibitor Indenoisoquinoline LMP-400 by the Cell Checkpoint and Chk1-Chk2 Inhibitor AZD7762
Cancer Research

74 (15)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/74/15

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.